German science and technology group Merck KGaA (MRK: DE) has upgraded its full-year outlook after a second quarter in which its laboratory and semiconductor materials businesses more than covered a ...

UK-based clinical-stage pharma company Actimed Therapeutics today revealed that it has regained exclusive global rights to the anabolic-catabolic transforming agent (ACTA) S-oxprenolol from US biotech ...

US pharma major Eli Lilly (NYSE: LLY) reported second-quarter 2026 revenue of $23 billion, up 48% year-on-year from $15.6 billion in the second quarter of 2025 and well ahead of Wall Street forecasts ...

Adneuris Therapeutics, a wholly-owned subsidiary of Tris Pharma advancing a new kind of pain medicine, announced that it has ...

There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted ...

Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved ...

Borealis Bio emerged from stealth in August 2024 with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research ...

A Chinese biotech company developing medicines for people with serious liver diseases. Hexaell Biotech, founded in 2015 in Shanghai, specializes in innovative therapies for severe liver diseases, ...

Aarvik Therapeutics combines a unique, proprietary modular platform with multiple target mechanisms to develop new molecules with an improved therapeutic index for oncology and other diseases. Backed ...

US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity ...

US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology.

Swiss affordable medicines company Sandoz today presented its financial results for the first half of 2026 and net-sales ...